Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has completed a series of studies evaluating the safety and anti-inflammatory, anti-aging, and antimicrobial properties of its cannabigerol (“CBG”) when used on skin. The studies were conducted in collaboration with Signum Biosciences Inc., … Continue reading “CBDNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Completion of Groundbreaking Study on CBG Use on Skin”
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has announced its fourth-quarter and full-year numbers for the period ended Dec. 31, 2020. In the report, Willow noted that it had filed a short form base shelf prospectus that allowed the company … Continue reading “CBDNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Q4 and FY 2020 Financial, Operational Report”
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has made advancements on its work on a proprietary yeast strain for the production of Tetrahydrocannabinol (“THC”); the company also announced plans to commercially launch the product in the highly regulated, legal Canadian … Continue reading “CBDNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Update on THC, Plans for Canadian Market Launch”
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) has contracted with a leading manufacturer to produce its first cannabinoid, cannabigerol (“CBG”); the first production run is slated for early 2021 and will result in commercial quantities of Willow’s ultra-pure CBG. The product will be manufactured in Europe. In addition, Willow announced plans to run a second 500-litre … Continue reading “CBDNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Progress in Commercialization Plan with Initial Product Expected in Q1 2021”
Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF), a Canadian biotechnology company and a leading developer in biosynthetically produced cannabidiol (“CBD”), this morning issued a release commenting on the recent news that the U.S. Drug Enforcement Agency (“DEA”) has removed Purisys, LLC’s CBD from Schedule I of the Controlled Substances Act (“CSA”). Purisys, the spin-out entity … Continue reading “CBDNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Comments on DEA Descheduling Partner’s CBD”
Willow’s plan to provide biosynthetic cannabinoid has potential to disrupt the cannabis-industry supply chain Biosynthetically derived cannabinoids offer unique advantages related to reliability, scalability, quality and cost Key collaboration allows company to capitalize on enormous market opportunity Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF), an emerging biotechnology company focused on the biosynthetic production of cannabinoids, … Continue reading “Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) Eyes Opportunity to Provide Biosynthetic Cannabinoids in Market with Explosive Potential”
Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) today announced that it has been approved to commence trading on the OTCQB® Venture Market (the “OTCQB”), under the symbol “CANSF,” beginning today, November 5, 2019. The listing will enable Willow Biosciences access to a broader base of U.S. and international retail and institutional investors, ultimately providing increased … Continue reading “CBDNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) to Begin Trading on the OTCQB® Venture Market”
Willow Biosciences (CSE: WLLW) recently entered a joint development agreement (“JDA”) with leading cannabinoid manufacturer Noramco Inc. to develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol (“CBD”) (http://cnw.fm/KZdi0). An article further discussing the company reads, “The JDA is mutually exclusive and creates an enviable arrangement designed to take advantage of each company’s unique … Continue reading “CBDNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Joint Development Agreement to Create Biosynthesis Platform for CBD Production, Distribution”
Canada-based Willow Biosciences (CSE: WLLW) was recently featured in a video by InvestmentPitch Media detailing how the company utilizes its proprietary biosynthetic processes to deliver high yields of ultra-pure, low-cost cannabinoids. An article further discussing the company reads, “The video (http://cnw.fm/7MJm1) highlights a recent joint development agreement between Alberta, Canada-based Willow Biosciences and Delaware-headquartered Noramco … Continue reading “CBDNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Employs Proprietary Biosynthetic Processes to Develop Ultra-Pure CBD”
A joint development agreement signed with Noramco Inc., the world’s largest producer of chemically synthesized cannabinoids and pharmaceutical APIs, is expected to scale the development of Willow’s CBD biosynthesis program The collective market for CBD sales in the U.S. is expected to exceed $20 billion by 2024, while the cannabinoid-based pharmaceuticals market may reach $50 … Continue reading “Willow Biosciences Inc. (CSE: WLLW) Developing Biosynthesis Platform for Production of Low-Cost, Pharmaceutical-Grade CBD”
